| Name | Title | Contact Details |
|---|
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.
Boston Ivf is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BRI Biopharmaceutical Research Inc is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Paradigm Capital Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
HealthTrio LLC is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.